Form 8-K - Current report:
SEC Accession No. 0000950170-23-003048
Filing Date
2023-02-16
Accepted
2023-02-16 16:08:22
Documents
14
Period of Report
2023-02-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20230216.htm   iXBRL 8-K 53202
2 EX-99.1 rare-ex99_1.htm EX-99 451307
3 GRAPHIC img45776771_0.jpg GRAPHIC 375412
  Complete submission text file 0000950170-23-003048.txt   1156963

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rare-20230216.xsd EX-101.SCH 2475
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rare-20230216_lab.xml EX-101.LAB 12806
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rare-20230216_pre.xml EX-101.PRE 9457
8 EXTRACTED XBRL INSTANCE DOCUMENT rare-20230216_htm.xml XML 4516
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 23638590
SIC: 2834 Pharmaceutical Preparations